Amy Early

940 total citations
29 papers, 642 citations indexed

About

Amy Early is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Amy Early has authored 29 papers receiving a total of 642 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Amy Early's work include Acute Lymphoblastic Leukemia research (7 papers), Advanced Breast Cancer Therapies (6 papers) and Acute Myeloid Leukemia Research (5 papers). Amy Early is often cited by papers focused on Acute Lymphoblastic Leukemia research (7 papers), Advanced Breast Cancer Therapies (6 papers) and Acute Myeloid Leukemia Research (5 papers). Amy Early collaborates with scholars based in United States, Canada and Cuba. Amy Early's co-authors include Harvey D. Preisler, Harry K. Slocum, Azra Raza, George P. Browman, Michelle J. Marinello, Martin L. Brecher, Sandhya Pruthi, James A. Simon, Arnold I. Freeman and Ellis Levine and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Amy Early

29 papers receiving 563 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Early United States 12 346 268 230 151 127 29 642
Jeffrey Jacobsen United States 7 206 0.6× 166 0.6× 165 0.7× 101 0.7× 74 0.6× 10 502
Josefine Palle Sweden 17 659 1.9× 363 1.4× 216 0.9× 300 2.0× 53 0.4× 58 912
Christine von Neuhoff Germany 16 736 2.1× 422 1.6× 155 0.7× 302 2.0× 45 0.4× 24 889
Óscar González‐Llano Mexico 19 588 1.7× 284 1.1× 165 0.7× 91 0.6× 55 0.4× 71 924
Samuel Kopel United States 8 369 1.1× 179 0.7× 197 0.9× 155 1.0× 59 0.5× 14 628
April Sorrell United States 9 314 0.9× 201 0.8× 90 0.4× 114 0.8× 30 0.2× 18 498
Keiichi Isoyama Japan 15 400 1.2× 289 1.1× 99 0.4× 187 1.2× 46 0.4× 50 705
R. Schlenk Germany 10 473 1.4× 180 0.7× 96 0.4× 183 1.2× 31 0.2× 20 629
Amal Al-Seraihy Saudi Arabia 15 275 0.8× 117 0.4× 98 0.4× 120 0.8× 65 0.5× 47 559
U. Creutzig Germany 11 456 1.3× 287 1.1× 103 0.4× 140 0.9× 26 0.2× 35 550

Countries citing papers authored by Amy Early

Since Specialization
Citations

This map shows the geographic impact of Amy Early's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Early with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Early more than expected).

Fields of papers citing papers by Amy Early

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Early. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Early. The network helps show where Amy Early may publish in the future.

Co-authorship network of co-authors of Amy Early

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Early. A scholar is included among the top collaborators of Amy Early based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Early. Amy Early is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Perimbeti, Stuthi, Kristopher Attwood, Hongbin Chen, et al.. (2024). Patients' Preferences for Adjuvant Osimertinib in Non–Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?. Clinical Lung Cancer. 25(6). 509–518. 2 indexed citations
2.
3.
Gandhi, Shipra, Mateusz Opyrchal, Melissa Grimm, et al.. (2023). Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx. Journal for ImmunoTherapy of Cancer. 11(11). e007381–e007381. 10 indexed citations
4.
Early, Amy, Mary E. Reid, Kelvin H. Lee, et al.. (2023). Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). 9135–9135. 7 indexed citations
5.
Gandhi, Shipra, Peter Forsyth, Mateusz Opyrchal, et al.. (2023). Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer.. Journal of Clinical Oncology. 41(16_suppl). TPS1112–TPS1112. 2 indexed citations
6.
7.
Roy, Arya Mariam, Kristopher Attwood, Tracey L. O’Connor, et al.. (2022). Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience. Frontiers in Oncology. 12. 1012391–1012391. 11 indexed citations
8.
Nesline, Mary, Sarabjot Pabla, Yong Hee Lee, et al.. (2022). Comprehensive genomic and immune profiling (CGIP) treatment patterns and survival in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 40(16_suppl). e21167–e21167. 1 indexed citations
9.
Lang, Jennifer K., Adolfo Quiñones‐Lombraña, Rachael Hageman Blair, et al.. (2021). CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin. Cardio-Oncology. 7(1). 17–17. 11 indexed citations
10.
Thomas, Roby, Ellis Levine, Adam Brufsky, et al.. (2020). Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. Breast Cancer Basic and Clinical Research. 14. 2222502368–2222502368. 27 indexed citations
11.
Early, Amy, et al.. (2020). Breast Cancer and Secondary Cancer Recurrences After Autologous Tissue Reconstruction. Clinical Breast Cancer. 21(1). e96–e101. 7 indexed citations
12.
Levine, Ellis, Kilian Salerno, Fan Zhang, et al.. (2018). Efficacy of Palbociclib Combinations in Hormone Receptor–Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment. Clinical Breast Cancer. 18(6). e1401–e1405. 21 indexed citations
13.
Khoury, Thaer, et al.. (2017). Neuroendocrine Carcinoma of the Breast With Endobronchial Metastases and Syndrome of Inappropriate Antidiuretic Hormone Secretion. Clinical Breast Cancer. 17(5). e229–e232. 1 indexed citations
14.
Harer, Matthew W., et al.. (2017). Implementation of a multidisciplinary guideline improves preterm infant admission temperatures. Journal of Perinatology. 37(11). 1242–1247. 35 indexed citations
15.
Zhang, Fan, Ellis Levine, Stephen B. Edge, et al.. (2017). Outcome of palbociclib based therapy in hormone receptor positive metastatic breast cancer patients after treatment with everolimus.. Journal of Clinical Oncology. 35(15_suppl). 1054–1054. 3 indexed citations
16.
Pruthi, Sandhya, James A. Simon, & Amy Early. (2011). Current Overview of the Management of Urogenital Atrophy in Women with Breast Cancer. The Breast Journal. 17(4). 403–408. 42 indexed citations
17.
Preisler, Harvey D., Azra Raza, Amy Early, et al.. (1987). Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.. Journal of Clinical Oncology. 5(5). 722–730. 68 indexed citations
18.
Ozer, Howard, Tao Han, Amy Early, et al.. (1983). An Improved Method for T-Cell Depletion of Allogeneic Histoincompatible Donor Bone Marrow. PubMed. 1(1). 79–86. 2 indexed citations
19.
Preisler, Harvey D., et al.. (1983). Therapy of Secondary Acute Nonlymphocytic Leukemia with Cytarabine. New England Journal of Medicine. 308(1). 21–23. 107 indexed citations
20.
Rustum, Y. M., et al.. (1982). Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment. Medical and Pediatric Oncology. 10(S1). 33–43. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey Jacobsen Breakdown of academic impact, for papers by Josefine Palle Breakdown of academic impact, for papers by Christine von Neuhoff Breakdown of academic impact, for papers by Óscar González‐Llano Breakdown of academic impact, for papers by Samuel Kopel Breakdown of academic impact, for papers by April Sorrell Breakdown of academic impact, for papers by Keiichi Isoyama Breakdown of academic impact, for papers by R. Schlenk Breakdown of academic impact, for papers by Amal Al-Seraihy Breakdown of academic impact, for papers by U. Creutzig
Rankless by CCL
2026